Next Article in Journal
Quantitative Assessment of Grapevine Wood Colonization by the Dieback Fungus Eutypa lata
Next Article in Special Issue
MIC Distributions and Evaluation of Fungicidal Activity for Amphotericin B, Itraconazole, Voriconazole, Posaconazole and Caspofungin and 20 Species of Pathogenic Filamentous Fungi Determined Using the CLSI Broth Microdilution Method
Previous Article in Journal / Special Issue
Antifungal Susceptibility Testing of Fusarium: A Practical Approach
Open AccessArticle

An Assessment of In Vitro Antifungal Activities of Efinaconazole and Itraconazole against Common Non-Dermatophyte Fungi Causing Onychomycosis

1
Department of Microbiology, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra University, Porur, Chennai Tamilnadu 600116, India
2
Jhaveri Microbiology Centre, LV Prasad Eye Institute, Kallam Anji Reddy Campus, L V Prasad Marg, Banjara Hills, Hyderabad Telangana 500034, India
3
Department of Microbiology, Kempegowda Institute of Medical Sciences, Athibabbe Road, Banashankari Stage II, Banashankari, Bengaluru Karnataka 560070, India
4
Department of Dermatology, Venereology & Leprosy, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra University, Porur, Chennai Tamilnadu 600116, India
*
Author to whom correspondence should be addressed.
Academic Editors: Ana Alastruey-Izquierdo and Stéphane Ranque
J. Fungi 2017, 3(2), 20; https://doi.org/10.3390/jof3020020
Received: 25 February 2017 / Revised: 27 April 2017 / Accepted: 3 May 2017 / Published: 5 May 2017
(This article belongs to the Special Issue Antifungal Susceptibility Testing)
Onychomycosis is a fungal nail infection which is relatively common and difficult to treat. Treatment modalities include nail avulsion, surgical debridement and combination therapy with oral and topical antifungal drugs. In spite of a host of available drugs, clinical cure rates remain discouraging. Drug toxicities, prolonged regimens, lack of patient compliance, and high keratin affinity of drugs are all contributive factors. Efinaconazole is a novel topical triazole antifungal agent that has shown excellent in vitro activity against both dermatophyte and non-dermatophyte fungi causing onychomycosis. This study presents the in vitro susceptibility profiles of 44 common non-dermatophyte fungi against efinaconazole and itraconazole, another azole drug used in the treatment of onychomycosis. View Full-Text
Keywords: antifungal susceptibility testing; Fusarium; Aspergillus; CLSI; efinaconazole; itraconazole; onychomycosis antifungal susceptibility testing; Fusarium; Aspergillus; CLSI; efinaconazole; itraconazole; onychomycosis
Show Figures

Figure 1

MDPI and ACS Style

Tupaki-Sreepurna, A.; Jishnu, B.T.; Thanneru, V.; Sharma, S.; Gopi, A.; Sundaram, M.; Jyoti Kindo, A. An Assessment of In Vitro Antifungal Activities of Efinaconazole and Itraconazole against Common Non-Dermatophyte Fungi Causing Onychomycosis. J. Fungi 2017, 3, 20.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop